CA2652976C - High affinity antibodies to human il-6 receptor - Google Patents

High affinity antibodies to human il-6 receptor Download PDF

Info

Publication number
CA2652976C
CA2652976C CA2652976A CA2652976A CA2652976C CA 2652976 C CA2652976 C CA 2652976C CA 2652976 A CA2652976 A CA 2652976A CA 2652976 A CA2652976 A CA 2652976A CA 2652976 C CA2652976 C CA 2652976C
Authority
CA
Canada
Prior art keywords
antibody
antigen
seq
hil
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2652976A
Other languages
English (en)
French (fr)
Other versions
CA2652976A1 (en
Inventor
Sean Stevens
Tammy T. Huang
Joel H. Martin
Jeanette L. Fairhurst
Ashique Rafique
Eric Smith
Kevin J. Pobursky
Nicholas J. Papadopoulos
James P. Fandl
Gang Chen
Margaret Karow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38792460&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2652976(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of CA2652976A1 publication Critical patent/CA2652976A1/en
Application granted granted Critical
Publication of CA2652976C publication Critical patent/CA2652976C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
CA2652976A 2006-06-02 2007-06-01 High affinity antibodies to human il-6 receptor Active CA2652976C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US81066406P 2006-06-02 2006-06-02
US60/810,664 2006-06-02
US84323206P 2006-09-08 2006-09-08
US60/843,232 2006-09-08
PCT/US2007/013062 WO2007143168A2 (en) 2006-06-02 2007-06-01 High affinity antibodies to human il-6 receptor

Publications (2)

Publication Number Publication Date
CA2652976A1 CA2652976A1 (en) 2007-12-13
CA2652976C true CA2652976C (en) 2015-08-11

Family

ID=38792460

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2652976A Active CA2652976C (en) 2006-06-02 2007-06-01 High affinity antibodies to human il-6 receptor

Country Status (33)

Country Link
US (10) US7582298B2 (OSRAM)
EP (2) EP2374818B1 (OSRAM)
JP (3) JP5307708B2 (OSRAM)
KR (1) KR101464502B1 (OSRAM)
CN (2) CN102585002A (OSRAM)
AT (1) ATE537190T1 (OSRAM)
AU (1) AU2007254831B2 (OSRAM)
BR (1) BRPI0712224B8 (OSRAM)
CA (1) CA2652976C (OSRAM)
CR (1) CR10462A (OSRAM)
CY (3) CY1112456T1 (OSRAM)
DK (2) DK2041177T3 (OSRAM)
ES (2) ES2398076T3 (OSRAM)
GT (1) GT200800272A (OSRAM)
HR (2) HRP20120175T1 (OSRAM)
HU (1) HUS1700050I1 (OSRAM)
IL (1) IL195393A (OSRAM)
LT (1) LTC2041177I2 (OSRAM)
LU (1) LUC00050I2 (OSRAM)
ME (1) ME00519B (OSRAM)
MX (1) MX2008014804A (OSRAM)
MY (2) MY147468A (OSRAM)
NL (1) NL300911I2 (OSRAM)
NO (2) NO340778B1 (OSRAM)
NZ (2) NZ573557A (OSRAM)
PL (2) PL2374818T3 (OSRAM)
PT (2) PT2374818E (OSRAM)
RS (2) RS52176B (OSRAM)
RU (1) RU2433138C2 (OSRAM)
SI (2) SI2041177T1 (OSRAM)
SV (1) SV2008003113A (OSRAM)
TN (1) TNSN08502A1 (OSRAM)
WO (1) WO2007143168A2 (OSRAM)

Families Citing this family (379)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
SI1523496T1 (sl) 2002-07-18 2011-11-30 Merus B V Rekombinantno proizvajanje zmesi protiteles
EP2395017A3 (en) 2003-05-30 2012-12-19 Merus B.V. Design and use of paired variable regions of specific binding molecules
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
KR101239051B1 (ko) 2005-10-21 2013-03-04 추가이 세이야쿠 가부시키가이샤 심장질환 치료제
EP2006381B1 (en) * 2006-03-31 2016-02-03 Chugai Seiyaku Kabushiki Kaisha Method for controlling blood pharmacokinetics of antibodies
WO2007116962A1 (ja) 2006-04-07 2007-10-18 Osaka University 筋再生促進剤
US8080248B2 (en) 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
NZ573557A (en) 2006-06-02 2010-08-27 Regeneron Pharma High affinity antibodies to human il-6 receptor
AU2007285695B2 (en) * 2006-08-18 2012-05-24 Ablynx N.V. Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
JP2010510796A (ja) * 2006-11-30 2010-04-08 アストラゼネカ アクチボラグ インターロイキン−６とインターロイキン−６受容体との複合体に特異的な抗体
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
ES2564392T3 (es) 2007-01-23 2016-03-22 Shinshu University Inhibidores de IL-6 para el tratamiento de rechazo crónico
US8178101B2 (en) * 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US7906117B2 (en) * 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
US8404235B2 (en) * 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US20090238825A1 (en) * 2007-05-21 2009-09-24 Kovacevich Brian R Novel rabbit antibody humanization methods and humanized rabbit antibodies
CN105001332B (zh) 2007-05-21 2018-12-04 奥尔德生物控股有限责任公司 针对il-6的抗体及其用途
KR20100028571A (ko) * 2007-05-21 2010-03-12 앨더 바이오파마슈티컬즈, 인코포레이티드 신규한 래빗 항체 인간화 방법 및 인간화된 래빗 항체
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
US8252286B2 (en) 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
BRPI0815370B8 (pt) 2007-08-10 2021-05-25 Regeneron Pharma anticorpos humanos de alta afinidade contra o fator de crescimento neural humano e seu uso, molécula de ácido nucleico, vetor de expressão, método para produção de um anticorpo anti-ngf humano e composiçao farmacêutica
RU2505603C2 (ru) 2007-09-26 2014-01-27 Чугаи Сейяку Кабусики Кайся Антитело против рецептора il-6
CL2008002886A1 (es) * 2007-09-26 2009-12-04 Chugai Pharmaceutical Co Ltd Region constante de un anticuerpo humano; anticuerpo anti-receptor de interleucina-6 (il-6) y composicion farmaceutica que la comprende.
CA2700701C (en) 2007-09-26 2020-12-29 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
NZ717429A (en) 2008-04-11 2018-07-27 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
US8034344B2 (en) 2008-05-13 2011-10-11 Novimmune S.A. Anti-IL-6/IL-6R antibodies and methods of use thereof
WO2009143472A2 (en) * 2008-05-23 2009-11-26 Aliva Biopharmaceuticals, Inc. Method of generating single vl domain antibodies in transgenic animals
KR101665729B1 (ko) 2008-06-05 2016-10-12 국립연구개발법인 고쿠리츠간켄큐센터 신경침윤 억제제
EP2556747B1 (en) 2008-06-27 2020-12-02 Merus N.V. Antibody producing transgenic mice
TWI440469B (zh) * 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
AU2012200724B8 (en) * 2008-09-26 2014-09-11 Chugai Seiyaku Kabushiki Kaisha Improved antibody molecules
WO2010056948A2 (en) 2008-11-13 2010-05-20 Femta Pharmaceuticals, Inc. Humanized anti-il-6 antibodies
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
CA2744103C (en) 2009-02-24 2018-01-02 Esbatech, An Alcon Biomedical Research Unit Llc Methods for identifying immunobinders of cell-surface antigens
SG10201408247SA (en) * 2009-02-24 2015-02-27 Esbatech Alcon Biomed Res Unit Methods for identifying immunobinders of cell-surface antigens
EP2826789A1 (en) 2009-03-19 2015-01-21 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
WO2010106812A1 (en) * 2009-03-19 2010-09-23 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical formulation containing improved antibody molecules
WO2010107110A1 (ja) 2009-03-19 2010-09-23 中外製薬株式会社 抗体定常領域改変体
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
EP2417162A2 (en) * 2009-04-10 2012-02-15 Ablynx N.V. Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
WO2010115998A2 (en) 2009-04-10 2010-10-14 Ablynx Nv Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
PT2564695E (pt) 2009-07-08 2015-06-03 Kymab Ltd Modelos animais e moléculas terapêuticas
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
HRP20240920T1 (hr) 2009-10-26 2024-10-11 F. Hoffmann - La Roche Ag Postupak za proizvodnju glikoziliranog imunoglobulina
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
US20120294852A1 (en) 2009-11-24 2012-11-22 Smith Jeffrey T L Antagonists of il-6 to raise albumin and/or lower crp
CN104131035A (zh) 2009-12-10 2014-11-05 瑞泽恩制药公司 生产重链抗体的小鼠
JO3274B1 (ar) 2009-12-24 2018-09-16 Regeneron Pharma أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
AR080428A1 (es) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
JO3183B1 (ar) 2010-01-29 2018-03-08 Regeneron Pharma طرق لمعالجة أمراض المناعة الذاتية مضادات dll4
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
DK2505654T4 (da) 2010-02-08 2020-07-27 Regeneron Pharma Mus med fælles letkæde
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
EP3190187A1 (en) * 2010-05-21 2017-07-12 Peptimed, Inc. Reagents and methods for treating cancer
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
PL2578231T3 (pl) 2010-05-28 2023-01-16 Chugai Seiyaku Kabushiki Kaisha Środek wzmacniający przeciwnowotworową odpowiedź limfocytów t
KR101900435B1 (ko) 2010-06-16 2018-09-20 트렐리스 바이오싸이언스 인코포레이티드 인간 사이토메갈로바이러스 gB 단백질에 대한 고친화도 인간 항체
CA3250882A1 (en) 2010-08-02 2025-11-29 Regeneron Pharamaceuticals, Inc. Mice that Make Binding Proteins Comprising VL Domains
AR083044A1 (es) * 2010-09-27 2013-01-30 Regeneron Pharma Anticuerpos anti-cd48 y usos de los mismos
US9533039B2 (en) 2010-09-27 2017-01-03 Regeneron Pharmaceuticals, Inc. Methods of treating systemic lupus erythematosus (SLE) using anti-CD48 antibodies
JO3375B1 (ar) 2010-11-08 2019-03-13 Regeneron Pharma أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a)
JO3756B1 (ar) 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
CA2818813C (en) 2010-11-23 2020-10-06 Alder Biopharmaceuticals, Inc. Anti-il-6 antibodies for the treatment of oral mucositis
CN108715614A (zh) 2010-11-30 2018-10-30 中外制药株式会社 与多分子的抗原重复结合的抗原结合分子
WO2012098238A1 (en) 2011-01-21 2012-07-26 Novimmune S.A. Combination therapies and methods using anti-cd3 modulating agents and anti-il-6 antagonists
MX366458B (es) 2011-01-28 2019-07-10 Sanofi Biotechnology Composiciones farmaceuticas que comprenden anticuerpos humanos frente a pcsk9.
SI2738258T2 (sl) 2011-02-25 2023-05-31 Regeneron Pharmaceuticals, Inc. Miši ADAM6
JP6097702B2 (ja) * 2011-03-03 2017-03-15 アペクシジェン， インコーポレイテッド 抗ｉｌ−６受容体抗体およびその使用方法
US11028149B2 (en) 2011-04-01 2021-06-08 Chugai Seiyaku Kabushiki Kaisha Recombinant polypeptide production method
DK2527842T3 (da) 2011-05-12 2013-09-08 Regeneron Pharma Neuropeptidfrisætningsanalyse til natriumkanaler
AR087329A1 (es) 2011-06-17 2014-03-19 Regeneron Pharma Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
MY172718A (en) 2011-08-05 2019-12-11 Regeneron Pharma Humanized universal light chain mice
WO2013041844A2 (en) 2011-09-19 2013-03-28 Kymab Limited Antibodies, variable domains & chains tailored for human use
CA2849195A1 (en) 2011-09-23 2013-03-28 Ablynx Nv Prolonged inhibition of interleukin-6 mediated signaling
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
ES2694153T3 (es) 2011-09-30 2018-12-18 Regeneron Pharmaceuticals, Inc. Anticuerpos anti-ErbB3 y usos de los mismos
KR20200039028A (ko) * 2011-10-11 2020-04-14 사노피 바이오테크놀로지, 소시에떼 빠르 악씨옹 셍쁠리피에 류마티스 관절염 치료를 위한 조성물 및 이의 이용방법
TWI589299B (zh) * 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
US9943594B2 (en) 2011-10-11 2018-04-17 Sanofi Biotechnology Methods for the treatment of rheumatoid arthritis
MY172946A (en) 2011-10-17 2019-12-16 Regeneron Pharma Restricted immunoglobulin heavy chain mice
WO2013059548A1 (en) 2011-10-19 2013-04-25 Sanofi Compositions and methods for treating cancer using jak2 inhibitor
WO2013059426A1 (en) * 2011-10-21 2013-04-25 The Regents Of The University Of California Human endogenous retrovirus peptides, antibodies to the peptides, and methods of use thereof
CN103059137A (zh) * 2011-10-21 2013-04-24 神州细胞工程有限公司 抗hIL6R高亲和力抗体的制备及应用
RS55949B1 (sr) 2011-10-28 2017-09-29 Regeneron Pharmaeuticals Inc Humanizovani il-6 i il-6 receptor
JO3370B1 (ar) * 2011-11-10 2019-03-13 Regeneron Pharma طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
EP2780368B1 (en) 2011-11-14 2018-01-03 Regeneron Pharmaceuticals, Inc. Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and/or activin a
PL2782598T3 (pl) 2011-11-23 2021-03-08 In3Bio Ltd. Rekombinowane białka i ich zastosowania terapeutyczne
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
KR102081657B1 (ko) 2011-12-20 2020-02-26 리제너론 파마슈티칼스 인코포레이티드 인간화 경쇄 마우스
HUE056335T2 (hu) * 2012-01-31 2022-02-28 Regeneron Pharma ASIC1-ellenes antitestek és alkalmazásaik
US9371383B2 (en) 2012-01-31 2016-06-21 Regeneron Pharmaceuticals, Inc. Anti-ASIC1 antibodies and uses thereof
TWI613215B (zh) 2012-02-22 2018-02-01 再生元醫藥公司 抗－大－內皮素－１（ｂｉｇ－ｅｔ－１）抗體及其用途
CN104203976A (zh) 2012-03-02 2014-12-10 瑞泽恩制药公司 艰难梭状芽孢杆菌毒素的人源抗体
JP2015509380A (ja) 2012-03-06 2015-03-30 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 共通の軽鎖のマウス
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
ES2665793T3 (es) 2012-03-16 2018-04-27 Regeneron Pharmaceuticals, Inc. Anticuerpos de cadena ligera modificada mediante ingeniería genética con histidina y roedores modificados genéticamente para la generación de los mismos
CN104302170B (zh) 2012-03-16 2016-09-28 瑞泽恩制药公司 生产具有ph依赖性结合特性的抗原结合蛋白的小鼠
NZ730271A (en) 2012-03-16 2022-09-30 Regeneron Pharma Non-human animals expressing ph-sensitive immunoglobulin sequences
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
TWI619729B (zh) 2012-04-02 2018-04-01 再生元醫藥公司 抗－ｈｌａ－ｂ*２７抗體及其用途
CA2870821C (en) 2012-04-20 2022-06-14 Merus B.V. Methods and means for the production of ig-like molecules
JO3820B1 (ar) 2012-05-03 2021-01-31 Regeneron Pharma أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
HUE055617T2 (hu) 2012-06-12 2021-12-28 Regeneron Pharma Korlátozott immunglobulin nehézlánc lókuszokkal rendelkezõ, humanizált, nem humán élõlények
TWI641619B (zh) 2012-06-25 2018-11-21 美商再生元醫藥公司 抗－ｅｇｆｒ抗體及其用途
KR102307248B1 (ko) 2012-08-21 2021-10-01 사노피 바이오테크놀로지 Il-4r 길항제의 투여에 의한 천식의 치료 또는 예방 방법
JO3462B1 (ar) 2012-08-22 2020-07-05 Regeneron Pharma أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
NZ630178A (en) 2012-09-07 2017-06-30 Regeneron Pharma Methods for treating atopic dermatitis by administering an il-4r antagonist
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
US20140134189A1 (en) 2012-11-13 2014-05-15 Regeneron Pharmaceuticals, Inc. Anti-prokineticin receptor (prokr) antibodies and uses thereof
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
ES2678221T3 (es) 2013-02-20 2018-08-09 Regeneron Pharmaceuticals, Inc. Animales no humanos con secuencias de cadena pesada de inmunoglobulina modificadas
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
LT3501272T (lt) 2013-03-13 2023-03-27 Regeneron Pharmaceuticals, Inc. Pelės, vykdančios imunoglobulino lengvosios grandinės riboto rinkinio raišką
EP2970437A1 (en) 2013-03-13 2016-01-20 Regeneron Pharmaceuticals, Inc. Common light chain mouse
HK1220468A1 (zh) 2013-03-14 2017-05-05 Regeneron Pharmaceuticals, Inc. Nav1．7的人抗体
MX369574B (es) 2013-03-14 2019-11-13 Regeneron Pharma Anticuerpos humanos contra grem1.
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
EP3009518B1 (en) 2013-06-11 2020-08-12 National Center of Neurology and Psychiatry Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (rrms) patient, and method for determining applicability of novel therapy
MX368068B (es) 2013-06-21 2019-09-18 Sanofi Biotechnology Antagonista de il-4r para usarse para tratar la poliposis nasal.
TW201920262A (zh) 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素ａ之抗體及其用途
WO2015027154A2 (en) 2013-08-23 2015-02-26 Regeneron Pharmaceuticals, Inc. Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit)
SG10201810825YA (en) 2013-09-18 2019-01-30 Regeneron Pharma Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
GB201316644D0 (en) 2013-09-19 2013-11-06 Kymab Ltd Expression vector production & High-Throughput cell screening
NL2013554B1 (en) 2013-10-01 2016-01-08 Kymab Ltd Animal models and therapeutic molecules.
WO2015066259A1 (en) 2013-10-31 2015-05-07 Regeneron Pharmaceuticals, Inc. Competitive ligand binding assay for detecting neutralizing antibodies
EA201691027A1 (ru) 2013-11-20 2016-12-30 Ридженерон Фармасьютикалз, Инк. Модуляторы aplnr и их применение
US8945560B1 (en) 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
DE202014010499U1 (de) 2013-12-17 2015-10-20 Kymab Limited Targeting von humaner PCSK9 zur Cholesterinbehandlung
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
WO2015095511A2 (en) * 2013-12-20 2015-06-25 The Scripps Research Institute Functional antibodies that modulate cell death and related methods
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
WO2015116852A1 (en) 2014-01-29 2015-08-06 Regeneron Pharmaceuticals, Inc. Methods for treating rheumatoid arthritis by administering an il-6r antibody
IL315136A (en) 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
CN106459199B (zh) 2014-03-11 2021-01-01 瑞泽恩制药公司 抗-egfrviii抗体及其用途
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
BR112016021679A2 (pt) 2014-03-21 2018-12-04 Regeneron Pharmaceuticals, Inc. proteína de ligação ao antígeno, métodos de produção de uma proteína de ligação ao antígeno e de identificação de uma ou mais proteínas de ligação ao antígeno, hibridoma, ácido nucleico, célula, e, animal não humano geneticamente modificado.
BR112016021572A2 (pt) 2014-03-21 2017-10-03 Regeneron Pharma Métodos para preparar um animal não humano geneticamente modificado e para produzir proteínas de ligação, hibridoma, ácido nucleico, célula, e, proteína de ligação
JO3701B1 (ar) 2014-05-23 2021-01-31 Regeneron Pharma مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي
JP2017533695A (ja) 2014-09-16 2017-11-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗グルカゴン抗体およびその使用
SG10201913084PA (en) 2014-09-23 2020-03-30 Regeneron Pharma Anti-il-25 antibodies and uses thereof
AU2015334984A1 (en) 2014-10-21 2017-04-13 Ablynx Nv Treatment of IL-6R related diseases
CA2967602C (en) 2014-11-14 2024-09-24 Regeneron Pharmaceuticals, Inc. METHODS OF TREATMENT OF CHRONIC SINUSITIS WITH NASAL POLYPOSIS BY ADMINISTRATION OF AN IL-4R ANTAGONIST
SMT202000438T1 (it) 2014-11-17 2020-09-10 Regeneron Pharma Metodi per trattamento di tumore usando l'anticorpo bispecifico cd3xcd20
AU2015355150A1 (en) * 2014-12-02 2017-06-08 Regeneron Pharmaceuticals, Inc. Methods for treating dry eye disease by administering an IL-6R antagonist
TWI702229B (zh) 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
TWI710573B (zh) 2015-01-26 2020-11-21 美商再生元醫藥公司 抗伊波拉病毒醣蛋白之人類抗體
EP4269440A3 (en) 2015-02-27 2024-02-28 Chugai Seiyaku Kabushiki Kaisha Composition for treating il-6-related diseases
CA2979702A1 (en) 2015-03-19 2016-09-22 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
WO2016159213A1 (ja) 2015-04-01 2016-10-06 中外製薬株式会社 ポリペプチド異種多量体の製造方法
IL255010B2 (en) 2015-04-15 2024-01-01 Regeneron Pharma Methods of increasing strength and functionality with gdf8 inhibitors
JP2016208934A (ja) * 2015-05-12 2016-12-15 学校法人日本大学 抗イヌインターロイキン−６受容体モノクローナル抗体又は抗体フラグメント及びその利用
EP3299810B1 (en) 2015-05-19 2021-07-07 National Center of Neurology and Psychiatry Method for determining application of novel therapy to multiple sclerosis (ms) patient
US11174317B2 (en) 2015-06-04 2021-11-16 National Center Of Neurology And Psychiatry Therapeutic agent for mental illness comprising IL-6 inhibitor as active ingredient
JP6993958B2 (ja) 2015-07-06 2022-02-04 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 多重特異性抗原結合分子およびその使用
JOP20160154B1 (ar) 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
TWI870789B (zh) 2015-08-04 2025-01-21 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
EA201890519A1 (ru) 2015-08-18 2018-07-31 Ридженерон Фармасьютикалз, Инк. Ингибирующие антитела против pcsk9 для лечения пациентов с гиперлипидемией, подвергающихся аферезу липопротеинов
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
EP3184547A1 (en) * 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anti-tpbg antibodies and methods of use
IL313952A (en) 2015-12-22 2024-08-01 Regeneron Pharma Combination of anti-PD-1 antibodies and bispecific anti-CD20 / anti-CD3 antibodies for cancer treatment
MX2018007781A (es) 2015-12-28 2018-09-05 Chugai Pharmaceutical Co Ltd Metodo para promover la eficiencia de purificacion del polipeptido que contiene la region de fragmento cristalizable (fc).
SG10201914034WA (en) 2016-01-13 2020-03-30 Regeneron Pharma Rodents having an engineered heavy chain diversity region
US20170247436A1 (en) 2016-02-16 2017-08-31 Regeneron Pharmaceuticals, Inc. Non-human animals having a mutant kynureninase gene
SG11201807614SA (en) 2016-03-07 2018-10-30 Sanofi Biotechnology Compositions and methods for treating rheumatoid arthritis
EP3216461A1 (en) 2016-03-07 2017-09-13 Sanofi Biotechnology Compositions and methods for treating rheumatoid arthritis
MX386832B (es) 2016-04-08 2025-03-19 Regeneron Pharma Inhibidor angptl8 e inhibidor angptl3 para usarse en el tratamiento de hiperlipidemia.
BR112018071283A2 (pt) * 2016-04-20 2019-02-12 Regeneron Pharma célula, conjunto de vetores para expressar uma proteína de ligação a antígeno biespecífica em uma célula, conjunto de vetores, método, e, método para produção de uma proteína de ligação a antígeno.
CA3015371A1 (en) * 2016-04-20 2017-10-26 Regeneron Pharmaceuticals, Inc. Compositions and methods for making antibodies based on use of an expression-enhancing locus
EP3448891A1 (en) 2016-04-28 2019-03-06 Regeneron Pharmaceuticals, Inc. Methods of making multispecific antigen-binding molecules
TWI822521B (zh) 2016-05-13 2023-11-11 美商再生元醫藥公司 藉由投予pd-1抑制劑治療皮膚癌之方法
JP7324583B2 (ja) 2016-05-20 2023-08-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 複数のガイドｒｎａを使用して免疫寛容を破綻させるための方法
WO2017201731A1 (en) * 2016-05-27 2017-11-30 Beijing Vdjbio Co., Ltd. Antibodies, composition and kits comprising same, and methods of use thereof
WO2017214089A1 (en) 2016-06-06 2017-12-14 Regeneron Pharmaceuticals, Inc. Non-human animals expressing antibodies with human lambda light chains
BR112018075434A2 (pt) 2016-06-10 2019-03-19 Regeneron Pharmaceuticals, Inc. anticorpo isolado ou fragmento de ligação de antígeno do mesmo, composição farmacêutica, e, métodos para tratar câncer e para modular resposta imune antitumor.
EP4374922A3 (en) 2016-06-14 2024-08-28 Regeneron Pharmaceuticals, Inc. Anti-c5 antibodies and uses thereof
TW201815821A (zh) 2016-07-18 2018-05-01 美商再生元醫藥公司 抗茲卡病毒抗體及使用方法
RU2656160C2 (ru) * 2016-08-17 2018-05-31 Закрытое Акционерное Общество "Биокад" Антитело или его антигенсвязывающий фрагмент, способный связываться с рецептором интерлейкина-6 человека
WO2018039499A1 (en) 2016-08-24 2018-03-01 Regeneron Pharmaceuticals, Inc. Host cell protein modification
US11771743B2 (en) 2016-09-01 2023-10-03 Regeneron Pharmaceuticals, Inc. Methods for preventing or treating allergy by administering an IL-4R antagonist
MY199468A (en) 2016-09-23 2023-10-31 Regeneron Pharma Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof
PT3515946T (pt) 2016-09-23 2022-08-04 Regeneron Pharma Anticorpos anti-muc16 (mucin 16)
DK3766343T3 (da) 2016-11-04 2022-06-20 Regeneron Pharma Ikke-humane dyr med et manipuleret immunoglobulin-lambda-letkædelocus
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
CN110036029A (zh) 2016-11-17 2019-07-19 瑞泽恩制药公司 用抗angptl8抗体处理肥胖的方法
EA201991283A9 (ru) 2016-11-29 2019-11-27 Фармацевтическая композиция для предотвращения опиоидной зависимости
MX2019006131A (es) 2016-11-29 2019-08-21 Regeneron Pharma Metodos para tratar cancer de mama positivo para prlr.
MA46952A (fr) 2016-12-01 2019-10-09 Regeneron Pharma Anticorps anti-pd-l1 radiomarqués pour imagerie immuno-pet
TWI857389B (zh) 2016-12-01 2024-10-01 美商再生元醫藥公司 治療發炎症狀的方法
WO2018118713A1 (en) 2016-12-22 2018-06-28 Regeneron Pharmaceuticals, Inc. Method of treating an allergy with allergen-specific monoclonal antibodies
TW202311284A (zh) 2017-01-03 2023-03-16 美商再生元醫藥公司 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體
MY200034A (en) 2017-02-10 2023-12-05 Regeneron Pharma Radiolabeled anti-lag3 antibodies for immuno-pet imaging
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
EP3620531A4 (en) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS
KR102674000B1 (ko) 2017-06-01 2024-06-11 리제너론 파마슈티칼스 인코포레이티드 Bet v 1에 대한 인간 항체 및 이것의 사용 방법
MA50546A (fr) 2017-06-07 2020-09-16 Regeneron Pharma Compositions et méthodes pour l'internalisation d'enzymes
AU2018287519B2 (en) 2017-06-22 2021-07-22 Novartis Ag IL-1beta binding antibodies for use in treating cancer
WO2018235056A1 (en) 2017-06-22 2018-12-27 Novartis Ag Il-1beta binding antibodies for use in treating cancer
CA3066779A1 (en) 2017-06-28 2019-01-03 Regeneron Pharmaceuticals, Inc. Anti-human papillomavirus (hpv) antigen-binding proteins and methods of use thereof
SG11201912548XA (en) 2017-07-06 2020-01-30 Regeneron Pharma Cell culture process for making a glycoprotein
TWI799432B (zh) 2017-07-27 2023-04-21 美商再生元醫藥公司 抗ctla-4抗體及其用途
JP2021500856A (ja) 2017-09-13 2021-01-14 江蘇恒瑞医薬股▲ふん▼有限公司 Ｉｌ−６ｒ抗体およびその抗原結合フラグメントならびに医薬としての使用
KR20200058525A (ko) 2017-09-29 2020-05-27 리제너론 파아마슈티컬스, 인크. 스타필로코커스 표적 항원 및 보체 성분에 결합하는 이특이적 항원-결합 분자 및 이의 용도
WO2019078344A1 (ja) 2017-10-20 2019-04-25 学校法人兵庫医科大学 抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物
EP4344706A3 (en) 2017-10-30 2024-05-22 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4r antagonist
BR112020006976A2 (pt) 2017-11-30 2020-10-13 Regeneron Pharmaceuticals, Inc. anticorpos monoclonais anti-trkb e métodos de uso
CN116058333A (zh) 2017-12-05 2023-05-05 瑞泽恩制药公司 具有经工程改造的免疫球蛋白λ轻链的非人动物以及所述非人动物的用途
SG11202004662RA (en) 2017-12-13 2020-06-29 Regeneron Pharma Anti-c5 antibody combinations and uses thereof
CN111542540A (zh) 2017-12-18 2020-08-14 瑞泽恩制药公司 结合瘦蛋白受体和/或gp130的双特异性抗原结合分子及其使用方法
WO2019126194A1 (en) 2017-12-18 2019-06-27 Regeneron Pharmaceuticals, Inc. Angptl8 assay and uses thereof
BR112020010615A2 (pt) 2017-12-22 2020-10-27 Regeneron Pharmaceuticals, Inc. produto farmacêutico proteico, método e sistema para caracterizar impurezas de produto farmacêutico proteico e de fármaco de baixo peso molecular, método para produzir um anticorpo, anticorpo, e, usos do método e do sistema
JP7372925B2 (ja) 2018-01-26 2023-11-01 リジェネロン・ファーマシューティカルズ・インコーポレイテッド インフルエンザヘマグルチニンに対するヒト抗体
SG11202005235WA (en) 2018-01-31 2020-07-29 Regeneron Pharma System and method for characterizing size and charge variant drug product impurities
TW202311746A (zh) 2018-02-02 2023-03-16 美商再生元醫藥公司 用於表徵蛋白質二聚合之系統及方法
AU2019218892B2 (en) 2018-02-07 2025-08-14 Regeneron Pharmaceuticals, Inc. Methods and compositions for therapeutic protein delivery
MX2020008988A (es) 2018-02-28 2020-09-28 Regeneron Pharma Sistemas y metodos para la identificacion de contaminantes virales.
MA52417A (fr) 2018-03-01 2021-01-06 Regeneron Pharma Procédés de modification de composition corporelle
US12259355B2 (en) 2018-03-19 2025-03-25 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
TW202516175A (zh) 2018-03-19 2025-04-16 美商再生元醫藥公司 微晶片毛細管電泳分析及試劑
US12253490B2 (en) 2018-03-19 2025-03-18 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
MA52175A (fr) 2018-03-26 2021-02-17 Regeneron Pharma Anticorps anti-pfrh5 et leurs fragments de liaison à l'antigène
KR102871690B1 (ko) 2018-04-30 2025-10-16 리제너론 파마슈티칼스 인코포레이티드 Her2 및/또는 aplp2에 결합하는 항체 및 이중특이적 항원-결합 분자 및 접합체 그리고 이들의 용도
KR20210008008A (ko) 2018-05-09 2021-01-20 리제너론 파마슈티칼스 인코포레이티드 항-msr1 항체 및 이의 사용 방법
TW202016125A (zh) 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
AU2019269685B2 (en) 2018-05-17 2025-12-04 Regeneron Pharmaceuticals, Inc. Anti-CD63 antibodies, conjugates, and uses thereof
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
MA52966A (fr) 2018-06-19 2021-04-28 Regeneron Pharma Anticorps anti-facteur xii/xiia et leurs utilisations
EP3810282A1 (en) 2018-06-21 2021-04-28 Regeneron Pharmaceuticals, Inc. Bispecific anti-psma x anti-cd28 antibodies and uses thereof
SMT202400102T1 (it) 2018-07-19 2024-05-14 Regeneron Pharma Recettori chimerici dell’antigene con specificità per bcma e loro usi
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAｘ抗-CD3抗體及其用途
MX2021001549A (es) 2018-08-10 2021-04-13 Regeneron Pharma Una composicion farmaceutica para el tratamiento seguro y efectivo del dolor de rodilla y/o cadera.
EP3840841A1 (en) 2018-08-23 2021-06-30 Regeneron Pharmaceuticals, Inc. Anti-fc epsilon-r1 alpha (fcer1a) antibodies, bispecific antigen-binding molecules that bind fcer1a and cd3, and uses thereof
CA3100035A1 (en) 2018-08-27 2020-03-05 Regeneron Pharmaceuticals, Inc. Use of raman spectroscopy in downstream purification
JP7504871B2 (ja) 2018-08-29 2024-06-24 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 関節リウマチを有する対象を治療するための方法および組成物
CA3100038A1 (en) 2018-08-30 2020-03-05 Regeneron Pharmaceuticals, Inc. Methods for characterizing protein complexes
CA3115102A1 (en) 2018-10-23 2020-04-30 Regeneron Pharmaceuticals, Inc. Anti-npr1 antibodies and uses thereof
CA3117945A1 (en) * 2018-11-09 2020-05-14 University Of Massachusetts Anti-cfae antibodies and methods of use
CN112867732A (zh) 2018-11-21 2021-05-28 瑞泽恩制药公司 抗葡萄球菌抗体和其用途
BR112021010238A2 (pt) 2018-12-19 2021-08-24 Regeneron Pharmaceuticals, Inc. Anticorpos anti-cd28 x anti-cd22 biespecíficos e usos dos mesmos
JP7588586B2 (ja) 2018-12-19 2024-11-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 二重特異性抗ｍｕｃ１６×抗ｃｄ２８抗体およびその使用
EP3897613A1 (en) 2018-12-21 2021-10-27 Novartis AG Use of il-1beta binding antibodies
EP3908303A4 (en) * 2019-01-07 2023-05-03 Hunan Siweikang Therapeutics Co. Ltd MODIFIED IMMUNE CELLS CO-EXPRESSING A CHIMERIC ANTIGEN RECEPTOR AND AN IL-6 ANTAGONIST TO REDUCE TOXICITY, AND USES THEREOF IN ADOPTIVE CELL THERAPY
MX2021008590A (es) 2019-01-16 2021-08-11 Regeneron Pharma Metodos para caracterizar enlaces de disulfuro.
AU2020216978B2 (en) 2019-01-31 2025-09-25 Regeneron Pharmaceuticals, Inc. Anti-il-6 receptor antibody for treating juvenile idiopathic arthritis
WO2020167919A1 (en) 2019-02-12 2020-08-20 Regeneron Pharmaceuticals, Inc. Compositions and methods for using bispecific antibodies to bind complement and a target antigen
JP2022523360A (ja) 2019-02-21 2022-04-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｍｅｔに結合する抗ｍｅｔ抗体および二特異性抗原結合分子を使用した眼癌の治療方法
WO2020178193A1 (en) 2019-03-01 2020-09-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Method of treatment of sarcoidosis
KR20210143246A (ko) 2019-03-21 2021-11-26 리제너론 파아마슈티컬스, 인크. 알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용
JP7659501B2 (ja) 2019-03-22 2025-04-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ＥＧＦＲｘＣＤ２８多特異性抗体
WO2020210551A1 (en) 2019-04-10 2020-10-15 Regeneron Pharmaceuticals, Inc. Human antibodies that bind ret and methods of use thereof
MA55760A (fr) 2019-04-24 2022-03-02 Regeneron Pharma Procédés de diagnostic et de traitement de la polyarthrite rhumatoïde
SG11202111255YA (en) 2019-05-01 2021-11-29 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-33 antagonist
MX2021013519A (es) 2019-05-13 2021-12-10 Regeneron Pharma Ensayos de union de ligandos competitivos mejorados.
BR112021024445A2 (pt) 2019-06-04 2022-02-15 Regeneron Pharma Composições e métodos para tratamento de dor em indivíduos com artrite reumatoide
KR20220016880A (ko) 2019-06-05 2022-02-10 리제너론 파마슈티칼스 인코포레이티드 카파 유전자좌에서 발현된 제한적 람다 경쇄 레퍼토리를 갖는 비-인간 동물 및 이의 용도
AU2020292283A1 (en) 2019-06-11 2021-12-23 Regeneron Pharmaceuticals, Inc. Anti-PcrV antibodies that bind PcrV, compositions comprising anti-PcrV antibodies, and methods of use thereof
AU2020291946A1 (en) * 2019-06-14 2022-01-06 Dana-Farber Cancer Institute, Inc. Antibodies against PD-1 and methods of use thereof
AU2020290971A1 (en) * 2019-06-14 2021-12-23 Dana-Farber Cancer Institute, Inc. Antibodies against PD-1 and methods of use thereof
US20200405883A1 (en) 2019-06-20 2020-12-31 Baxalta Incorporated Method of treatment with viral-based gene therapy
BR112022000740A2 (pt) 2019-07-16 2022-07-05 Sanofi Biotechnology Métodos para tratamento ou prevenção de asma por administração de um antagonista de il-4r
WO2021016585A1 (en) 2019-07-24 2021-01-28 Regeneron Pharmaceuticals, Inc. Chimeric antigen receptors with mage-a4 specificity and uses thereof
KR20220063185A (ko) 2019-09-16 2022-05-17 리제너론 파마슈티칼스 인코포레이티드 면역-pet 영상화를 위한 방사성 표지된 met 결합 단백질
KR20220066393A (ko) 2019-09-24 2022-05-24 리제너론 파아마슈티컬스, 인크. 크로마토그래피의 사용 및 재생을 위한 시스템 및 방법
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
BR112022007923A2 (pt) 2019-10-28 2022-07-26 Regeneron Pharma Anticorpo recombinante isolado ou fragmento de ligação ao antígeno deste, composição farmacêutica, molécula de polinucleotídeo, vetor, célula, e, método para prevenir, tratar ou melhorar pelo menos um sintoma da infecção por influenza
JP7682174B2 (ja) 2019-11-25 2025-05-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 非水性エマルションを使用した持続放出製剤
CA3160352A1 (en) 2019-12-06 2021-06-10 Israel Lowy Methods of treating multiple myeloma with bispecific anti-bcma x anti-cd3 antibodies
AU2020398168A1 (en) 2019-12-06 2022-07-28 Regeneron Pharmaceuticals, Inc. Methods for treating COPD by administering an IL-33 antagonist
CN115151568A (zh) 2019-12-23 2022-10-04 赛诺菲生物技术公司 用于通过施用il-33拮抗剂和/或il-4r拮抗剂以治疗或预防过敏性哮喘的方法
MY200781A (en) 2020-01-21 2024-01-15 Regeneron Pharma Deglycosylation methods for electrophoresis of glycosylated proteins
EP4093767A1 (en) 2020-01-22 2022-11-30 H. Lee Moffitt Cancer Center & Research Institute, Inc. Bi-specific chimeric antigen receptor t cells targeting cd83 and interleukin 6 receptor
AU2021219671A1 (en) 2020-02-10 2022-07-14 Regeneron Pharmaceuticals, Inc. Anti-Tmprss2 Antibodies and Antigen-Binding Fragments
MX2022009769A (es) 2020-02-11 2022-11-09 Regeneron Pharma Anticuerpos anti-acvr1 y usos de los mismos.
AU2021228225A1 (en) 2020-02-28 2022-09-01 Regeneron Pharmaceuticals, Inc. Bispecific antigen binding molecules that bind HER2, and methods of use thereof
AU2021232041A1 (en) 2020-03-06 2022-09-08 Regeneron Pharmaceuticals, Inc. Anti-GITR antibodies and uses thereof
KR102831970B1 (ko) 2020-04-02 2025-07-11 리제너론 파아마슈티컬스, 인크. 항-sars-cov-2 스파이크 당단백질 항체 및 항원-결합 단편
KR20230007470A (ko) * 2020-05-06 2023-01-12 소렌토 쎄라퓨틱스, 인코포레이티드 Sars-cov-2 s 단백질에 결합하는 중화 항체
US11884736B2 (en) 2020-05-12 2024-01-30 Regeneron Pharmaceuticals, Inc. Antibodies which bind to glucagon-like peptide 1 receptor (GLP1R)
US20230167182A1 (en) * 2020-05-18 2023-06-01 Biosion Inc. Antibodies binding il6r and uses thereof
AU2021281119A1 (en) 2020-05-26 2023-02-02 Sanofi Biotechnology Compositions comprising an antibody against interleukin-6 receptor for the treatment of rheumatoid arthritis and methods of using same
EP4157868A1 (en) 2020-05-26 2023-04-05 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
MX2022015030A (es) 2020-05-29 2023-01-04 Sanofi Biotechnology Composiciones y metodos para el tratamiento del dolor no inflamatorio en sujetos con artritis reumatoide.
US20230227539A1 (en) * 2020-06-16 2023-07-20 Hifibio (Hk) Limited Methods and compositions related to neutralizing antibodies against human coronavirus
WO2022032139A1 (en) * 2020-08-07 2022-02-10 Sorrento Therapeutics, Inc. Neutralizing antibodies that bind the sars-cov-2 s protein
CN116249713A (zh) 2020-08-20 2023-06-09 瑞泽恩制药公司 利用激活素a拮抗剂预防和治疗心功能不全和covid-19的方法
EP4204449A1 (en) 2020-08-26 2023-07-05 Regeneron Pharmaceuticals, Inc. Method of treating an allergy with allergen-specific monoclonal antibodies
CA3192999A1 (en) 2020-08-31 2022-03-03 Regeneron Pharmaceuticals, Inc. Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants
IL301137A (en) 2020-09-11 2023-05-01 Regeneron Pharma Identification and production of antigen-specific antibodies
JP2023543152A (ja) 2020-09-18 2023-10-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｃｄ３８及び／又はｃｄ２８を結合する抗原結合分子及びその使用
CA3194111A1 (en) 2020-10-05 2022-04-14 Christine XU Methods for treating asthma in pediatric subjects by administering an il-4r antagonist
JP7767411B2 (ja) 2020-10-22 2025-11-11 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ｆｇｆｒ２抗体及びその使用方法
IL303027A (en) 2020-11-25 2023-07-01 Regeneron Pharma Sustained release formulations by creating a non-aqueous membrane emulsion
CA3205135A1 (en) 2020-12-17 2022-06-23 Regeneron Pharmaceuticals, Inc. Fabrication of protein-encapsulating microgels
WO2022133239A1 (en) 2020-12-18 2022-06-23 Regeneron Pharmaceuticals, Inc. Immunoglobulin proteins that bind to npr1 agonists
CA3165366A1 (en) 2020-12-23 2022-06-30 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding anchor modified antibodies and uses thereof
CA3202197A1 (en) 2021-01-20 2022-07-28 Reginald Smith Methods of improving protein titer in cell culture
US20220404369A1 (en) 2021-03-03 2022-12-22 Regeneron Pharmaceuticals, Inc. Systems and methods for quantifying and modifying protein viscosity
WO2022187626A1 (en) 2021-03-05 2022-09-09 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-variant-spike glycoprotein antibodies and antigen-binding fragments
WO2022204728A1 (en) 2021-03-26 2022-09-29 Regeneron Pharmaceuticals, Inc. Methods and systems for developing mixing protocols
EP4326765A1 (en) 2021-04-20 2024-02-28 Regeneron Pharmaceuticals, Inc. Human antibodies to artemin and methods of use thereof
KR20240005854A (ko) 2021-05-04 2024-01-12 리제너론 파아마슈티컬스, 인크. Mage-a4 특이성을 갖는 키메라 항원 수용체 및 이들의 용도
EP4334353A1 (en) 2021-05-04 2024-03-13 Regeneron Pharmaceuticals, Inc. Multispecific fgf21 receptor agonists and their uses
AU2022274888A1 (en) 2021-05-11 2023-12-07 Regeneron Pharmaceuticals, Inc. Anti-tmprss6 antibodies and uses thereof
US12012450B2 (en) 2021-06-01 2024-06-18 Les Laboratoires Servier Anti-NKG2A antibodies and compositions
EP4348234A1 (en) 2021-06-01 2024-04-10 Regeneron Pharmaceuticals, Inc. Micropchip capillary electrophoresis assays and reagents
TW202317623A (zh) 2021-06-14 2023-05-01 美商再生元醫藥公司 基於il2之治療劑及其使用方法
WO2023283134A1 (en) 2021-07-05 2023-01-12 Regeneron Pharmaceuticals, Inc. Utilization of antibodies to shape antibody responses to an antigen
MX2024000563A (es) 2021-07-14 2024-04-10 Regeneron Pharma Anticuerpos y fragmentos de union al antigeno anti-glicoproteína de la espícula de sars-cov-2.
EP4377345A1 (en) 2021-07-26 2024-06-05 Sanofi Biotechnology Methods for treating chronic spontaneous urticaria by administering an il-4r antagonist
TW202326138A (zh) 2021-09-08 2023-07-01 美商再生元醫藥公司 用於定量抗體及其他含Ｆｃ蛋白之高通量及基於質譜之方法
AU2022348521A1 (en) 2021-09-20 2024-04-04 Regeneron Pharmaceuticals, Inc. Methods of controlling antibody heterogeneity
EP4413364A2 (en) 2021-10-07 2024-08-14 Regeneron Pharmaceuticals, Inc. Systems and methods of ph modeling and control
MX2024004108A (es) 2021-10-07 2024-04-19 Regeneron Pharma Calibracion y correccion de medidor de ph.
CA3235380A1 (en) 2021-10-20 2023-04-27 Elizabeth Laws Methods for treating prurigo nodularis by administering an il-4r antagonist
CA3235457A1 (en) 2021-10-22 2023-04-27 Regeneron Pharmaceuticals, Inc. Factor xi a2 domain-binding antibodies and methods of use thereof
IL312372A (en) 2021-10-26 2024-06-01 Regeneron Pharma Systems and methods for producing laboratory water and dispersing laboratory water at different temperatures
EP4433500A1 (en) 2021-11-19 2024-09-25 Regeneron Pharmaceuticals, Inc. Methods and compositions for reducing centralized pain
CA3239802A1 (en) 2021-12-06 2023-06-15 Regeneron Pharmaceuticals, Inc. Antagonist anti-npr1 antibodies and methods of use thereof
US20230296559A1 (en) 2022-03-18 2023-09-21 Regeneron Pharmaceuticals, Inc. Methods and systems for analyzing polypeptide variants
WO2023196903A1 (en) 2022-04-06 2023-10-12 Regeneron Pharmaceuticals, Inc. Bispecific antigen-binding molecules that bind and cd3 and tumor associated antigens (taas) and uses thereof
WO2023212586A1 (en) 2022-04-27 2023-11-02 Regeneron Pharmaceuticals, Inc. Methods for selecting patients for treatment with an ngf antagonist
EP4525993A1 (en) 2022-05-18 2025-03-26 Regeneron Pharmaceuticals, Inc. Multispecific antigen binding molecules that bind cd38 and 4-1bb, and uses thereof
EP4554977A1 (en) 2022-07-12 2025-05-21 Regeneron Pharmaceuticals, Inc. Antibodies to ciliary neurotrophic factor receptor (cntfr) and methods of use thereof
CN120091829A (zh) 2022-08-29 2025-06-03 赛诺菲生物技术公司 通过施用il-4r拮抗剂治疗慢性诱导性寒冷性荨麻疹的方法
IL320397A (en) 2022-11-07 2025-06-01 Regeneron Pharma Antibodies binding to the catalytic domain of factor XI and methods of using them
US20240190978A1 (en) 2022-11-15 2024-06-13 CSBioAsset LLC Compositions and methods for immunomodulatory bifunctional fusion molecules
WO2024130165A1 (en) 2022-12-16 2024-06-20 Regeneron Pharmaceuticals, Inc. Angptl3 inhibitors for triglyceride reduction in multifactorial chylomicronemia syndrome
EP4634659A1 (en) 2022-12-16 2025-10-22 Regeneron Pharmaceuticals, Inc. Methods and systems for assessing chromatographic column integrity
AU2024207469A1 (en) 2023-01-13 2025-08-28 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof
US20240245779A1 (en) 2023-01-25 2024-07-25 Regeneron Pharmaceuticals, Inc. Methods of modeling liquid protein composition stability
WO2024158961A1 (en) 2023-01-25 2024-08-02 Regeneron Pharmaceuticals, Inc. Mass spectrometry-based characterization of antibodies co-expressed in vivo
TW202445138A (zh) 2023-02-01 2024-11-16 美商再生元醫藥公司 用於生物巨分子分析之具質譜法的不對稱流場流分離
KR20250150011A (ko) 2023-02-13 2025-10-17 리제너론 파마슈티칼스 인코포레이티드 항-인간 cacng1 항체를 이용한 근육 관련 장애 치료
US20240299601A1 (en) 2023-02-17 2024-09-12 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-lag3 antibodies for immuno-pet imaging
US20240280551A1 (en) 2023-02-22 2024-08-22 Regeneron Pharmaceuticals, Inc. System suitability parameters and column aging
AU2024241290A1 (en) 2023-03-22 2025-11-06 Regeneron Pharmaceuticals, Inc. Methods for treating chronic obstructive pulmonary disease (copd) by administering an il-4r antagonist
WO2024229136A1 (en) 2023-05-01 2024-11-07 Regeneron Pharmaceuticals, Inc. Multidose antibody drug products using phenol or benzyl alcohol
CN121039163A (zh) 2023-05-02 2025-11-28 瑞泽恩制药公司 抗人m-钙粘蛋白（cdh15）抗体、缀合物及其用于将遗传有效负载递送至肌肉细胞的用途
WO2024259206A1 (en) 2023-06-16 2024-12-19 Regeneron Pharmaceuticals, Inc. Cd40 x cd40 bispecific antigen-binding molecules and uses thereof
US20250043017A1 (en) 2023-07-10 2025-02-06 Regeneron Pharmaceuticals, Inc. BISPECIFIC PD-L1x4-1BB ANTIBODIES AND METHODS OF USE THEREOF
WO2025014913A1 (en) 2023-07-10 2025-01-16 Regeneron Pharmaceuticals, Inc. Bispecific pd-l1xcd28 antibodies and methods of use thereof
WO2025014533A1 (en) 2023-07-10 2025-01-16 Regeneron Pharmaceuticals, Inc. Anti-human cacng1 antibody-drug conjugates and uses thereof
CN119285767B (zh) * 2023-07-10 2025-11-18 东莞市朋志生物科技有限公司 抗白介素-6抗体、检测白介素-6的试剂和试剂盒
WO2025019789A1 (en) 2023-07-19 2025-01-23 Regeneron Pharmaceuticals, Inc. ANTI-FACTOR XII/XIIa ANTIBODIES AND USES THEREOF
WO2025054406A1 (en) 2023-09-08 2025-03-13 Regeneron Pharmaceuticals, Inc. Methods and systems for assessing chromatographic column integrity
US20250095773A1 (en) 2023-09-18 2025-03-20 Regeneron Pharmaceuticals, Inc. Methods and systems for developing chromatography protocols
TW202532098A (zh) 2023-09-29 2025-08-16 美商再生元醫藥公司 使用控制成核之冷凍乾燥
WO2025085594A1 (en) 2023-10-18 2025-04-24 Regeneron Pharmaceuticals, Inc. Rapid purification of monoclonal antibody from in-process upstream cell culture material
US20250145662A1 (en) 2023-11-02 2025-05-08 Regeneron Pharmaceuticals, Inc. Methods for reducing lipase activity using stress
WO2025149846A1 (en) 2024-01-12 2025-07-17 Sanofi Biotechnology Compositions and methods for treating frail subjects with polymyalgia rheumatica by administering an il-6r antagonist
WO2025149845A1 (en) 2024-01-12 2025-07-17 Sanofi Biotechnology Treatment of subjects with polymyalgia rheumatica who have been receiving a steroid
WO2025166281A1 (en) 2024-02-01 2025-08-07 Regeneron Pharmaceuticals, Inc. Platform for charge-detection mass spectrometry analysis of aavs
WO2025175164A1 (en) 2024-02-16 2025-08-21 Regeneron Pharmaceuticals, Inc. Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods
WO2025194043A1 (en) 2024-03-15 2025-09-18 Regeneron Pharmaceuticals, Inc. Polysorbate and polyoxyethylene sorbitan as excipients for stable protein formulations
WO2025221640A1 (en) 2024-04-15 2025-10-23 Sanofi Biotechnology Methods for treating chronic rhinosinusitis without nasal polyps by administering an il-4r antagonist
WO2025240335A1 (en) 2024-05-13 2025-11-20 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof
WO2025259840A1 (en) 2024-06-13 2025-12-18 Regeneron Pharmaceuticals, Inc. Methods and systems for scaled chromatography
CN119775414B (zh) * 2025-03-12 2025-06-06 武汉伊莱瑞特生物科技股份有限公司 抗猴白介素-6单克隆抗体、酶联免疫检测试剂盒及其应用

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670373A (en) 1988-01-22 1997-09-23 Kishimoto; Tadamitsu Antibody to human interleukin-6 receptor
CA1341152C (en) * 1988-01-22 2000-12-12 Tadamitsu Kishimoto Receptor protein for human b cell stimulatory factor-2
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5216128A (en) 1989-06-01 1993-06-01 Yeda Research And Development Co., Ltd. IFN-β2/IL-6 receptor its preparation and pharmaceutical compositions containing it
CA2021594C (en) * 1989-07-20 2002-01-08 Tadamitsu Kishimoto Antibody to human interleukin-6 receptor
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DE122009000019I1 (de) 1991-04-25 2009-07-16 Chugai Seiyaku K K 5 1 Rekombinierte humane antikörper gegen den humanen interleukin-6 rezeptor
JPH05227970A (ja) * 1992-02-19 1993-09-07 Chugai Pharmaceut Co Ltd ヒトインターロイキン−６受容体に対する再構成ヒト抗体
FR2694767B1 (fr) * 1992-08-13 1994-10-21 Innotherapie Lab Sa Anticorps monoclonaux anti-IL6R, et leurs applications.
JPH09505721A (ja) 1992-10-20 1997-06-10 シータス オンコロジー コーポレイション インターロイキン６レセプターアンタゴニスト
US5888511A (en) * 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
US5888510A (en) 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
AU7967294A (en) * 1993-10-06 1995-05-01 Board Of Regents, The University Of Texas System A monoclonal anti-human il-6 receptor antibody
ATE552012T1 (de) 1994-10-07 2012-04-15 Chugai Pharmaceutical Co Ltd Hemmung des abnormalen wachstums von synovialzellen durch il-6-antagonisten als wirkstoff
EP0791359A4 (en) * 1994-10-21 2002-09-11 Chugai Pharmaceutical Co Ltd MEDICINE AGAINST IL-6 PRODUCTION IN DISEASES
EP0800829B2 (en) 1994-12-29 2012-07-25 Chugai Seiyaku Kabushiki Kaisha Use of a pm-1 antibody or of a mh 166 antibody for enhancing the anti-tumor effect of cisplatin or carboplatin
ES2264135T3 (es) * 1995-02-13 2006-12-16 Chugai Seiyaku Kabushiki Kaisha Inhibidor de la descomposicion de proteinas musculares que contienen anticuerpos frente al receptor de il-6.
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US5785965A (en) 1996-05-15 1998-07-28 The Board Of Trustees Of The Leland Stanford Junior Univ. VEGF gene transfer into endothelial cells for vascular prosthesis
EP0923941B1 (en) 1996-06-27 2006-05-17 Chugai Seiyaku Kabushiki Kaisha Remedies for myeloma to be used together with nitrogen mustard antitumor agents
US20020187150A1 (en) * 1997-08-15 2002-12-12 Chugai Seiyaku Kabushiki Kaisha Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
DE69839517D1 (de) 1997-08-15 2008-07-03 Chugai Pharmaceutical Co Ltd Präventiva oder arzneien enthaltend neutralisierende anti-il6-rezeptor antikörper zur reduktion urinären proteins bei systemischen lupus erythematosus
CA2324115C (en) 1998-03-17 2008-12-23 Chugai Seiyaku Kabushiki Kaisha A preventive or therapeutic agent for inflammatory bowel disease comprising il-6 antagonist as an active ingredient
DK1108435T3 (da) 1998-08-24 2007-02-05 Chugai Pharmaceutical Co Ltd Forebyggende midler eller midler mod pancreatitis indeholdende anti-IL-6-receptor-antistoffer som den aktive bestanddel
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
EP2311492B1 (en) 2000-08-11 2017-10-04 Chugai Seiyaku Kabushiki Kaisha Antibody-containing stabilized preparations
CA2424371A1 (en) 2000-10-20 2003-04-01 Chugai Seiyaku Kabushiki Kaisha Agonistic monoclonal antibody fragments
AU1095202A (en) * 2000-10-25 2002-05-06 Chugai Pharmaceutical Co Ltd Preventives or remedies for psoriasis containing as the active ingredient il-6 antagonist
WO2002036165A1 (fr) * 2000-10-27 2002-05-10 Chugai Seiyaku Kabushiki Kaisha Agent à base d'antagoniste d'il-6, faisant baisser le niveau des mmp-3 dans le sang
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
UA80091C2 (en) * 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
MXPA04007924A (es) 2002-02-14 2005-05-17 Chugai Pharmaceutical Co Ltd Formulaciones en solucion que contienen anticuerpo.
US20060275294A1 (en) * 2002-08-22 2006-12-07 Omoigui Osemwota S Method of prevention and treatment of aging, age-related disorders and/or age-related manifestations including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimers disease and cancer
US20060078533A1 (en) * 2004-10-12 2006-04-13 Omoigui Osemwota S Method of prevention and treatment of aging and age-related disorders including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimer's disease and cancer
US20060078532A1 (en) * 2004-10-12 2006-04-13 Omoigui Osemwota S Method of prevention and treatment of Atherosclerosis, Peripheral vascular disease, Coronary artery disease, aging and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease
US20060078531A1 (en) * 2004-10-12 2006-04-13 Osemwota Sota Method of prevention and treatment of atherosclerosis, peripheral vascular disease, coronary artery disease, and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease
CN1678744B (zh) * 2002-08-30 2010-05-26 财团法人化学及血清疗法研究所 人的抗人白细胞介素-6抗体以及所述抗体的片段
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US7534427B2 (en) * 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
WO2005028514A1 (en) 2003-09-22 2005-03-31 Biovation Gmbh & Co. Kg. Use of a compound for reducing the biological effectiveness of il-6
US8617550B2 (en) * 2003-12-19 2013-12-31 Chugai Seiyaku Kabushiki Kaisha Treatment of vasculitis with IL-6 antagonist
JP2008505054A (ja) * 2004-02-11 2008-02-21 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー Ｉｌ−６アンタゴニストで骨関節炎を治療する方法
US20070036788A1 (en) * 2004-09-22 2007-02-15 Ahmed Sheriff Use of a compound for reducing the biological effectiveness of il-6
JPWO2006046661A1 (ja) * 2004-10-28 2008-05-22 国立大学法人大阪大学 インターロイキン−６阻害剤
JP2008524242A (ja) * 2004-12-16 2008-07-10 ジェネンテック・インコーポレーテッド 自己免疫障害を治療する方法
WO2007094754A2 (en) * 2005-01-27 2007-08-23 The Regents Of The University Of Califordnia Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
US8080248B2 (en) 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
NZ573557A (en) * 2006-06-02 2010-08-27 Regeneron Pharma High affinity antibodies to human il-6 receptor
AU2007285695B2 (en) 2006-08-18 2012-05-24 Ablynx N.V. Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling
RU2319351C1 (ru) * 2006-09-13 2008-03-20 Олег Иванович Квасенков Способ подготовки к хранению яблок свежих специального назначения
JP2010507624A (ja) 2006-10-27 2010-03-11 アブリンクス エン．ヴェー． ポリペプチド及びタンパク質の鼻内送達
EP2666787B1 (en) 2007-05-31 2022-02-09 Genmab A/S STABLE IgG4 ANTIBODIES
WO2009095489A2 (en) 2008-02-01 2009-08-06 Ablynx N.V. Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
WO2009109584A1 (en) 2008-03-07 2009-09-11 Ferring International Center S. A. ANTIBODY BINDING ONLY TO IL6-sIL6R COMPLEX

Also Published As

Publication number Publication date
US20160229916A1 (en) 2016-08-11
SI2374818T1 (sl) 2013-03-29
PT2374818E (pt) 2013-02-13
BRPI0712224B1 (pt) 2020-11-17
US20100316627A1 (en) 2010-12-16
US20250206829A1 (en) 2025-06-26
JP2009539349A (ja) 2009-11-19
SI2041177T1 (sl) 2012-03-30
LUC00050I1 (OSRAM) 2017-11-22
US8043617B2 (en) 2011-10-25
CN101454345B (zh) 2012-08-08
RU2008152443A (ru) 2010-07-20
NL300911I2 (nl) 2018-02-01
JP6140777B2 (ja) 2017-05-31
HUS1700050I1 (hu) 2017-12-28
PL2041177T3 (pl) 2012-09-28
LTPA2017038I1 (lt) 2017-12-11
US20120003697A1 (en) 2012-01-05
US8183014B2 (en) 2012-05-22
CY2017039I2 (el) 2018-04-04
NO340778B1 (no) 2017-06-19
JP2013226143A (ja) 2013-11-07
US20210009698A1 (en) 2021-01-14
EP2041177B1 (en) 2011-12-14
TNSN08502A1 (en) 2010-04-14
US20140255995A1 (en) 2014-09-11
US20230094591A1 (en) 2023-03-30
US20070280945A1 (en) 2007-12-06
RU2433138C2 (ru) 2011-11-10
IL195393A0 (en) 2011-08-01
ES2377579T3 (es) 2012-03-29
US20130157313A1 (en) 2013-06-20
CY2017039I1 (el) 2018-04-04
SV2008003113A (es) 2009-10-27
NO20085309L (no) 2009-03-02
KR101464502B1 (ko) 2014-12-01
NZ573557A (en) 2010-08-27
AU2007254831A1 (en) 2007-12-13
JP5805703B2 (ja) 2015-11-04
US7582298B2 (en) 2009-09-01
BRPI0712224A2 (pt) 2012-01-17
EP2041177A2 (en) 2009-04-01
CY1112456T1 (el) 2015-12-09
IL195393A (en) 2013-07-31
WO2007143168A3 (en) 2008-04-24
MX2008014804A (es) 2009-01-27
US11370843B2 (en) 2022-06-28
AU2007254831B2 (en) 2012-03-22
MY159787A (en) 2017-01-31
RS52643B (sr) 2013-06-28
CN102585002A (zh) 2012-07-18
CA2652976A1 (en) 2007-12-13
DK2374818T3 (da) 2013-01-21
GT200800272A (es) 2009-08-21
CR10462A (es) 2009-03-20
NO2017060I1 (no) 2017-11-14
EP2374818A1 (en) 2011-10-12
DK2041177T3 (da) 2012-02-27
ATE537190T1 (de) 2011-12-15
JP5307708B2 (ja) 2013-10-02
US20190256606A1 (en) 2019-08-22
HRP20130228T1 (hr) 2013-04-30
MY147468A (en) 2012-12-14
ME00519B (me) 2011-10-10
KR20090024690A (ko) 2009-03-09
PT2041177E (pt) 2012-03-05
LUC00050I2 (OSRAM) 2018-01-23
BRPI0712224B8 (pt) 2021-05-25
NZ587107A (en) 2012-05-25
JP2016026171A (ja) 2016-02-12
HRP20120175T1 (hr) 2012-03-31
CY1113708T1 (el) 2016-06-22
WO2007143168A2 (en) 2007-12-13
US9884916B2 (en) 2018-02-06
RS52176B (sr) 2012-08-31
EP2374818B1 (en) 2012-12-19
US10584173B2 (en) 2020-03-10
PL2374818T3 (pl) 2013-05-31
ES2398076T3 (es) 2013-03-13
LTC2041177I2 (lt) 2018-09-10
CN101454345A (zh) 2009-06-10

Similar Documents

Publication Publication Date Title
US11370843B2 (en) High affinity antibodies to human IL-6 receptor
CA2664343C (en) High affinity human antibodies to human il-4 receptor

Legal Events

Date Code Title Description
EEER Examination request